BioBusiness Network 2007

As product pipelines continue to empty, and both finding and bringing new products to market becomes harder and more expensive, BioBusiness Network 2007 has evolved to meet your partnering needs. BioBusiness Network 2007 brings together the most senior level and influential executives in the industry: you’ll have the chance to book hundreds of 1-2-1 meetings over three days in addition to learning from the most topical case studies in the market place. To learn how to create valuable deal making opportunities and form the most dynamic partnerships around, its essential you sign up today for BioBusiness Network 2007!

13 Places Now Remaining For Europe’s Most Senior Biopartnering Event

Click Here To Register

Take Advantage Of The Numerous Networking Opportunities

Exchange Best Practice With Top Level Executives

Learn From Industry Leaders During The Panel Discussions

The Most Productive Biopartnering Event For 1-2-1 Meetings

Once again, BioBusiness Network 2007 will deliver a unique biopartnering experience that is unmatched at any other event:

• Greater seniority of participants, meaning you’re not wasting your time during discussions and you have the actual decision-maker right in front of you. 75% of delegates are CEO or VP level.

• The perfect audience and the perfect size for productive networking. 95% of delegates have direct responsibility for licensing, and with 250 delegates in attendance you have the opportunity of meeting every single one of them over 3 days.

• The perfect pharma-biotech split for meaningful networking. The pharma/biotech audience split is 50/50, meaning you’re not lost in a sea of competitors and you’re just as likely to bump into a potential future partner.

These pie charts describe the profile of the delegates that attend BioBusiness and whom you’ll be able to organise 1-2-1 meetings with. Once you are registered for the event, you will receive a special password to access our state-of-the-art online partnering system that allows you to pre-arrange meetings with all the conference delegates.

New: Get Private Coaching On Improving Your 1-2-1 Meeting Skills

For the first time at BioBusiness, we have hired the services of Christopher Barrat, a renowned speaker, writer and teacher of modern business communication and commercial skills with extensive experience of working with biotech and pharma companies.

In addition to giving a Guest Address on how to create maximum impact in your 1-2-1 meetings and first contact with Big Pharma, Christopher will be available for free private coaching sessions throughout the main conference so you can benefit from more tailored, individual advice.

“Christopher Barrat is great on communication skills, he can definitely help biotechs be more effective in their 1-2-1 meetings”
Dr Thomas Senderovitz, VP Global Clinical Pharmacology & Experimental Medicine, UCB

Get An Insight Into The Biggest And Most Creative Deals

Merck KGaA / Serono
The biggest acquisition of 2006 worth $13.3bn. Hear from Benoit Palms, Director of Licensing & Business Development at newly formed Merck Serono, how they are merging two separate licensing structures into a single organisation.

Sanofi-Aventis / Oxford Biomedica
Recently signed licensing agreement for Phase III candidate worth up to �518m and with an initial payment of �29m. Get the inside story on why Oxford Biomedica chose Sanofi-Aventis for this highly-coveted late-stage opportunity.

Merck / Sirna
One of the most expensive acquisitions of 2006, the $1.1bn acquisition of small biotech firm Sirna. Learn from Dr Ray Hill, Head of Licensing & External Research, Europe at Merck, why an acquisition was preferred to a licensing agreement.

GlaxoSmithKline / Genmab
Exclusive joint presentation by both GlaxoSmithKline and Genmab on one of the most complex and lucrative deals of recent times that spans multiple therapeutic areas and development stages.

Eli Lilly / Hypnion
Recently completed acquisition of Hypnion for $315m. Get the inside story on this multi-faceted deal that encompases both a pipeline and a platform technology from Dr Andrew Wood, Executive Director, Global External R&D Europe at Eli Lilly.

Pfizer / PowderMed
October 2006 acquisition of DNA-vaccine specialist PowderMed, the largest ever acquisition of a UK biotech. Learn from Alex Chanas, Senior Director, Worldwide Licensing & Business Development at Pfizer, why this vaccine acquisition was so critical to them.

Merck / Idera
Exclusive joint presentation by both Merck and Idera on innovative R&D collaboration agreement worth up to $455m. What are Merck’s realistic expectations for this early-stage opportunity?

AstraZeneca / Arrow Therapeutics
Recently signed $150m acquisition of anti-infectives biotech Arrow Therapeutics.

Nominate Yourself For The 5th Annual Innovative Bio-Partnering Awards 2007

Do you believe you have an open, flexible and innovative approach to deal-making that makes you a partner of choice in the biotech industry? And does everyone recognise this? Well this is your chance to prove it and gain the industry recognition you deserve by nominating yourself for these high-profile accolades.

Once again, BioBusiness Network 2007 will announce the winners of the industry’s 5th annual awards for innovation in deal-making during the evening dinner on the 19th of September 2007. For an application form and more information, click here.

Evaluate Your Financing Options In A Persistently Tough Funding Climate

The funding climate is getting no easier and VCs still seem reluctant to invest in early-stage opportunities, despite the more lucrative returns they offer. So what should you do if you’re an early-stage biotech? What are the critical success factors for attracting a good Series A financing round? And if you’ve recently completed an A-round, what do you need to have done with that funding to set yourself up for a successful Series B financing round? Since VCs are so reluctant, are you aware of how you can exploit private funding as an alternative? And what should you ultimately be aiming for, a trade sale or an IPO? If you want to understand the best ways to attract financing for your company, then the Biotech Funding Day on the 18th of September 2007 is a must. Click here for more details.

Exploit Niche, High-Margin Opportunities In The Promising Oncology Arena

As the appetite for discovering new blockbuster drugs seems to be diminishing, companies are turning their attention towards more niche opportunities that promise high margins in areas of unmet medical need. So to what extent should oncology provide the platform for the growth of this new business strategy within your organisation? What are the risks and opportunities associated with developing a strong focus on oncology? What can you learn from some of the most high-profile oncology deals of the last 12 months? Are oncology vaccine opportunities worth looking at or are they unlikely to deliver? And what are the current unmet medical needs in oncology? Join some of the world’s leading oncology specialists and deal-makers at the Oncology Deals Day on the 18th of September 2007 to find out just how significant the opportunities are in this space and how to access them. Click here for more details.